Skip to main content

Vertex Pharmaceuticals guidance

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

Vertex Pharmaceuticals gives no forecast in figures in its latest earnings release (2 Nov 2026). Many companies give their outlook on the call only, or none at all.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Guidance against results above 0 · within 1 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$13.10B to $13.20BRaised once—To come
Tax rate · AdjustedFY202619.5% to 20.5%Given once—To come
RevenueFY2025$11.90B to $12.00BRaised twice$12.00BWithin the range

VRTX in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.